期刊文献+

胸腺肿瘤常规适形与调强放疗的剂量学比较 被引量:3

Dosimetric Comparison of Conformal and Intensity Modulated Radiotherapy for the Patients with Thymoma and Thymic Carcinoma
下载PDF
导出
摘要 目的:探讨分别应用常规适形CRT与调强放疗技术IMRT治疗胸腺肿瘤的剂量分布优劣。材料与方法:选取8例胸腺肿瘤患者,分别制作适形与调强计划,所有计划均给予60Gy和70Gy两种处方剂量。对于计划的剂量体积直方图(DVH)、计划靶区(PTV)的靶区适形指数(CI)和靶区均匀指数(HI)以及正常组织的最大或最小剂量等指标进行分析。结果:调强计划的计划靶区CI及HI指数为0.77和1.04,适形计划为0.52和1.13。调强计划对于肺、脊髓、食道、气管、心脏和胸骨这些正常组织均显示出更好的保护效果。调强计划的肺V20和平均剂量为15.6%和8.67Gy,适形计划为18.8%和9.62Gy;调强计划的脊髓D1%为37.42Gy,适形计划为44.05Gy;调强计划的气管V30和平均剂量为32.61%和21.24Gy,适形计划为43.00%和24.73Gy;调强计划的食道V50和平均剂量为9.04%和21.74Gy,适形计划为18.96%和24.32Gy;调强计划的心脏V40和平均剂量为11.16%和11.29Gy,适形计划为13.93%和11.47Gy;调强计划的胸骨最大剂量和平均剂量为65.38Gy和43.50Gy,适形计划为68.96Gy和47.03Gy。结论:调强计划能够在提高靶区适形度和均匀性的同时,降低正常器官受量。 Objective: To evaluate the optimized conformal and IMRT plans for the patients with thymoma and thymic carcino- ma. Methods: For 8 patients with thymoma and thymic carcinoma, CRT and IMRT planning were preformed. Target doses for plans were 60 and 70 Gy. Plans were compared according to dose-volume histogram (DVH) analysis including conformity and homogeneity indices (CI and H/) of planning target volumes (PTVs), and maximum or mean doses to normal structures. Re- suits: CIs and His for IMRT plans were 0.77 and 1.04 while CRT 0.52 and 1.13. IMRT plans resulted in a better normal tissue sparing to Lung, Spinal Cord, Esophagus, Trachea, Heart and Stemal bone. V20 and Mean Dose of Lung were 15.6% and 8.67Gy (IMRT) vs. 18.8% and 9.62 Gy(CRT); Din of Spinal cord was 37.42(IMRT) vs. 44.05(CRT); V30 and Mean Dose of Trachea were 32.61% and 21.24 Gy (IMRT) vs. 43.00% and 24.73 Gy (CRT); Vs0 and Mean Dose of Esophagus were 9.04% and 21.74 Gy (IMRT) vs. 18.96% and 24.32 Gy(CRT); V4o and Mean Dose of Heart were 11.16% and 11.29 Gy (IMRT) vs. 13.93% arkl 11.47 Gy (CRT); Dmax and Mean Dose of provides superior target volume coverage and conformality, with de- creased dose to normal structures.
出处 《中国医学物理学杂志》 CSCD 2010年第1期1603-1606,1624,共5页 Chinese Journal of Medical Physics
关键词 胸腺瘤/胸腺癌 放射治疗 适形 调强 剂量 thymoma/ thymic carcinoma radiotherapy conformal intensity modulated dosimetry
  • 相关文献

参考文献3

二级参考文献16

  • 1Kiura K, Ueoka H, Segawa Y, Tabata M, Kakigawa H, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S,Takemoto M, Hiraki Y, Harada M, Tanimoto M. Phase Ⅰ/Ⅱ study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advancednon-small-cell lung cancer.British J Cancer 2003; 89:795-802.
  • 2Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three- dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:337-341.
  • 3Marks LB, Munley MT, Spencer DP, Sherouse GW, Bentel GC, Hoppenworth J, Chew M, Jaszczak RJ, Coleman RE,Proshitz LR. Quantification of radiation-induced regional lung with perfusion imaging. Int J Radiat Oncol Biol Phys 1997; 38:399-409.
  • 4Yoshizawa H, Tanaka J, Kagamu H, Maruyama Y, Miyao H,Ito K, Iwashima A, Suzuki E, Gejyo F. Phase Ⅰ/Ⅱ study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 2003; 89:803-807.
  • 5Antonadou D, Coliarakis N, Synodinou M, Athanassiou H,Kouveli A, Verigos C, Georgakopoulos G, Panoussaki K,Karageorgis P, Throuvalas N. Randomized phase Ⅲ trial of radiation treatment±amifostine in patients with advancedstage lung cancer. Int J Radiat Oncol Biol Phys 2001; 51:915-922.
  • 6Bradley JD, Ieumwananonthachai N, Purdy JA, Wasserman TH, Locktt M.A, Graham MV, Perez CA. Gross tumor volume,critical prognostic factor in patients treated with three-dimensional conformal radiation therpy for non-small-cell-lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52:49-57.
  • 7Northway MG, Libshitz HI, West JJ, Withers HR, Mukhopadhyay AK, Osborne BM, Szwarc IA, Dodd GD. The opossum an animal model for studying radiation esophagitis.Radiology 1979; 131:731-735.
  • 8Lepke RA, Libshitz HI. Radiation-induced injury of the esophagus. Radiology 1983; 148:375-378.
  • 9Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multiinstitutional phase II trial of paclitaxel, carboplatin,and concurrent radiation therapy for locally advanced non-small-cell cancer. J Clin Oncol 1998; 16:3316-3322.
  • 10Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach III M, Andras EJ. Interfraction interval dose not affect survival of patients with non-small cell lung can certreated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients.Int J Radiat Oncol Biol Phys 1999; 44:327-331.

共引文献12

同被引文献13

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部